C9orf72 — Chromosome 9 Open Reading Frame 72

C9orf72 (Chromosome 9 Open Reading Frame 72)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">C9orf72 — Chromosome 9 Open Reading Frame 72</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Toxic Species</td>
</tr>
<tr>
<td class="label">RNA toxicity</td>
<td>Sense/antisense foci</td>
</tr>
<tr>
<td class="label">DPR translation</td>
<td>poly-GR, poly-PR</td>
</tr>
<tr>
<td class="label">Loss of function</td>
<td>C9orf72 reduction</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als/ftd" style="color:#ef9a9a">ALS/FTD</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">AMYOTROPHIC LATERAL SCLEROSIS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">872 edges</a></td>
</tr>
</table>

Overview

C9orf72 (Chromosome 9 Open Reading Frame 72)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">C9orf72 — Chromosome 9 Open Reading Frame 72</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Toxic Species</td>
</tr>
<tr>
<td class="label">RNA toxicity</td>
<td>Sense/antisense foci</td>
</tr>
<tr>
<td class="label">DPR translation</td>
<td>poly-GR, poly-PR</td>
</tr>
<tr>
<td class="label">Loss of function</td>
<td>C9orf72 reduction</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als/ftd" style="color:#ef9a9a">ALS/FTD</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">AMYOTROPHIC LATERAL SCLEROSIS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">872 edges</a></td>
</tr>
</table>

Overview

[C9orf72](/genes/c9orf72) repeat expansion is the most common known genetic cause of familial [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) and [frontotemporal dementia](/diseases/frontotemporal-dementia), and a major molecular bridge across the ALS-FTD spectrum.[^1][@singh2026] Pathogenic GGGGCC repeat expansions in the first intron/promoter region drive a mixed loss-of-function and toxic gain-of-function biology involving RNA foci, dipeptide repeat proteins (DPRs), nucleocytoplasmic transport failure, and impaired proteostasis.[@li2026][@kurdi2026][@luong2026]

Genomic Architecture And Pathogenic Expansion

The normal C9orf72 repeat tract is short, while pathogenic alleles contain large expansions (often hundreds to thousands of repeats). Detection strategies include repeat-primed PCR and long-read approaches for difficult borderline alleles.[^1][@russell2026]

Key architecture points:

• Locus: chromosome 9p21.2.
• Pathogenic element: non-coding GGGGCC repeat expansion.
• Inheritance: autosomal dominant with age-dependent penetrance and variable expressivity.

Physiologic C9orf72 Function

C9orf72 protein forms a complex with SMCR8 and WDR41 that regulates endolysosomal trafficking and [autophagy](/entities/autophagy) initiation, with additional roles in immune signaling and lysosomal homeostasis.[@huang2026][@jiang2026] In [neurons](/entities/neurons) and myeloid-lineage cells, reduced C9orf72 expression can impair cargo clearance and stress adaptation, sensitizing systems already burdened by repeat toxicity.[@huang2026][@ross2026]

Core Pathogenic Mechanisms

1. RNA Foci Toxicity

Expanded sense and antisense transcripts form nuclear RNA foci that sequester RNA-binding proteins and alter splicing/translation programs.[@li2026][@lian2026] This mechanism can operate early, before frank neuronal loss.

2. RAN Translation And DPR Toxicity

Repeat-associated non-AUG translation produces poly-GA, poly-GR, poly-PR, poly-GP, and poly-PA peptides. Arginine-rich DPRs (GR/PR) disrupt ribosomal function[@jiang2026], phase-separated organelles, and nucleolar biology.[@kurdi2026][^12][^13]

3. Nucleocytoplasmic Transport Defects

C9-related RNA and DPR species interfere with nuclear pore and transport factors, resulting in impaired protein/RNA trafficking and downstream stress responses[@lian2026].[@luong2026][^14]

4. Loss-Of-Function And Immune Dysregulation

Lower C9orf72 expression can independently perturb lysosomal and immune pathways, especially in [microglia](/cell-types/microglia), potentially amplifying neuroinflammatory loops in ALS-FTD[@kurdi2026].[@jiang2026][@ross2026]

Clinical Phenotypes

ALS Phenotype

C9 carriers often present with limb or bulbar ALS, faster decline in subsets, and higher probability of cognitive/behavioral involvement compared with non-carriers.[@inami2026][^15]

FTD Phenotype

Behavioral variant FTD is common, with disinhibition/apathy syndromes and early executive dysfunction. Language variants also occur but are less frequent than in GRN-linked disease.[@singh2026][^15]

Mixed ALS-FTD And Psychiatric Features

The expansion is associated with psychosis and other neuropsychiatric features in a subset of families, emphasizing the need for broad phenotyping in precision trial enrollment.[^16]

Biomarker And Therapeutic-Target Relevance

C9orf72 is one of the best examples of a genetically defined precision-neurology target in neurodegeneration:

• Target engagement biomarkers: CSF poly(GP) is used in antisense and small-molecule programs as a pharmacodynamic marker of repeat transcript suppression.[^17]
• Fluid progression markers: [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) remains useful for risk/progression enrichment in symptomatic and presymptomatic carriers.[^18]
• Multimodal staging: combining genotype, fluid markers, cognition, and MRI network signatures improves power for early-phase studies.[^15][^18]

Therapeutic Landscape

Antisense Oligonucleotides (ASOs)

ASO strategies aim to reduce repeat-containing transcripts and downstream DPR production. Early trials established feasibility and target engagement, while efficacy optimization remains an active area.[^17][^19]

Small-Molecule And RNA-Targeting Approaches

Programs targeting repeat RNA structures, RAN translation, and stress granule dynamics are under development in preclinical and translational pipelines.[@lian2026][^13]

Pathway-Combination Strategies

Because C9 disease combines RNA toxicity, proteostasis failure, and neuroinflammation, combination strategies (repeat suppression plus clearance/inflammation modulation) are biologically plausible and increasingly prioritized.[@jiang2026][@ross2026][^19]

Research Gaps

• Better predictors of penetrance and age-at-onset are needed for preventive trial design.
• The relative contribution of loss-of-function versus DPR toxicity likely varies by stage and cell type.
• Longitudinal human data connecting biomarker shifts to meaningful clinical deltas remain limited.

See Also

• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/als)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [FTD with Motor Neuron Disease](/diseases/ftd-mnd)
• [Hexanucleotide Repeat Expansion](/c9orf72-hexanucleotide-repeat-expansion)
• [RNA Toxicity](/mechanisms/rna-toxicity)

External Links

• [C9orf72 Gene - NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/203523)
• [C9orf72 - ALS Association](https://www.als.org/)
• [C9orf72 Hexanucleotide Repeat Expansion - PubMed](https://pubmed.ncbi.nlm.nih.gov/21944779/)

Brain Atlas Resources

• Allen Human Brain Atlas: [Expression data for C9ORF72](https://human.brain-map.org/microarray/search/show?search_term=C9ORF72)
• Allen Cell Type Atlas: [Cell type expression data](https://celltype.brain-map.org/)
• BrainSpan Atlas: [Developmental transcriptome data](https://www.brainspan.org/)

Pathway Diagram

Disease Mechanism Summary

C9orf72 and 4R Tauopathies

A 2025 study examined whether intermediate C9orf72 repeat expansions represent a genetic risk factor for [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP), [corticobasal syndrome](/diseases/corticobasal-syndrome) (CBS), corticobasal degeneration (CBD), and atypical parkinsonism [1].

Key Findings

The PROSPECT study analyzed 626 clinical cases (366 PSP, 130 CBS, 53 atypical parkinsonism) plus 77 pathologically confirmed CBD cases:

• No significant difference in mean or largest allele size between affected patient groups and controls
• No significant difference in frequency of intermediate expansions between patients and controls
• No relationship found between repeat length and age at onset, disability level, or survival

Conclusion

Intermediate C9orf72 repeat expansions do not appear to be a genetic risk factor for PSP, CBS, CBD, or atypical parkinsonism. Pathogenic hexanucleotide repeat expansions remain the most common genetic cause of [frontotemporal dementia](/diseases/frontotemporal-dementia) and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), but intermediate repeats do not contribute to these atypical Parkinsonian disorders.

References

Pathway Diagram

The following diagram shows the key molecular relationships involving C9orf72 — Chromosome 9 Open Reading Frame 72 discovered through SciDEX knowledge graph analysis:

Associated Diseases

• ALS — associated with

• amyotrophic lateral sclerosis — causes

• Amyotrophic Lateral Sclerosis — associated with

• frontotemporal dementia — causes

• Frontotemporal dementia — causes